{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:47:55Z","timestamp":1791611275833,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014926","name":"Acceleron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Otsuka"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medimmune\/AstraZeneca"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trovagene"},{"name":"Incyte"},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADC Therapeutics"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015234","name":"Sunesis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013870","name":"Astex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013870","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CTI biopharma"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014597","name":"AI Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014597","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Samus Therapeutics"},{"DOI":"10.13039\/100016474","name":"Arog Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016474","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kartos Therapeutics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hoc.2020.11.005","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T09:41:45Z","timestamp":1610098905000},"page":"177-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"35","author":[{"given":"Rory M.","family":"Shallis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.11.005_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.005_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.11.005_bib5","series-title":"International classification of diseases for oncology","year":"2000"},{"issue":"17","key":"10.1016\/j.hoc.2020.11.005_bib6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.005_bib7","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.005_bib10","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2011-11-389866","article-title":"Unique features of primary myelofibrosis in Chinese","volume":"119","author":"Xu","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.005_bib11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib12","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.11.005_bib13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.11.005_bib14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2020.11.005_bib15","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.005_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","article-title":"Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing","volume":"59","author":"Kashofer","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.12684","article-title":"Smoking and Philadelphia-negative chronic myeloproliferative neoplasms","volume":"97","author":"Lindholm Sorensen","year":"2016","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canep.2013.03.012","article-title":"Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation","volume":"37","author":"Musselman","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.005_bib19","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib20","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ijc.28492","article-title":"Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort","volume":"134","author":"Leal","year":"2014","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.32853","article-title":"Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study","volume":"147","author":"Podoltsev","year":"2020","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.005_bib22","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/1055-9965.EPI-20-0592","article-title":"Diet and risk of myeloproliferative neoplasms in older individuals from the NIH-AARP Cohort","volume":"29","author":"Podoltsev","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","article-title":"The epidemiology of autoimmune diseases","volume":"2","author":"Cooper","year":"2003","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib24","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.005_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib27","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1097\/HS9.0000000000000327","article-title":"Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms","volume":"4","author":"Duncombe","year":"2020","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/oby.21863","article-title":"Obesity and related risk of myeloproliferative neoplasms among Israeli adolescents","volume":"25","author":"Leiba","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"9","key":"10.1016\/j.hoc.2020.11.005_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2018-06-858597","article-title":"Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms","volume":"132","author":"Sud","year":"2018","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.hoc.2020.11.005_bib30","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2020.11.005_bib31","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2012-05-430926","article-title":"Impact of isolated germline JAK2V617I mutation on human hematopoiesis","volume":"121","author":"Mead","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A\u00a0novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A\u00a0novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.11.005_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jclinpath-2016-203940","article-title":"Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms","author":"Szuber","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.005_bib36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A\u00a0germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14713","article-title":"Advances in understanding the pathogenesis of familial myeloproliferative neoplasms","volume":"178","author":"Rumi","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ijlh.12380","article-title":"JAK2 46\/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients","volume":"37","author":"Macedo","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-013-1295-y","article-title":"JAK2 46\/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients","volume":"97","author":"Tanaka","year":"2013","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.005_bib42","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2013.21","article-title":"JAK2V617F allele burden, JAK2 46\/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.leukres.2011.09.029","article-title":"Influence of JAK2 46\/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms","volume":"36","author":"Alvarez-Larran","year":"2012","journal-title":"Leuk Res"},{"issue":"44","key":"10.1016\/j.hoc.2020.11.005_bib44","doi-asserted-by":"crossref","first-page":"76204","DOI":"10.18632\/oncotarget.19211","article-title":"Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population","volume":"8","author":"Chiang","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.005_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ajh.23842","article-title":"Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms","volume":"89","author":"Jager","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.005_bib46","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/leu.2014.48","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms","volume":"28","author":"Oddsson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.11.005_bib47","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2020.11.005_bib50","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.005_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.11.005_bib53","author":"About"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.11.005_bib55","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib56","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/ajh.25407","article-title":"Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014","volume":"94","author":"Baade","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ejh.12788","article-title":"Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway","volume":"98","author":"Roaldsnes","year":"2017","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.005_bib59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ajh.21333","article-title":"Jakking up tumor registry reporting of the myeloproliferative neoplasms","volume":"84","author":"Selinger","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00277-016-2902-9","article-title":"Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013","volume":"96","author":"Byun","year":"2017","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.005_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.005_bib64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.25351","article-title":"20+ Years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients","volume":"94","author":"Penna","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.hoc.2020.11.005_bib68","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.hoc.2020.11.005_bib69","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.005_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.005_bib71","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/carcin\/bgq286","article-title":"Chromosome-wide aneuploidy study (CWAS) in workers exposed to an established leukemogen, benzene","volume":"32","author":"Zhang","year":"2011","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.005_bib72","doi-asserted-by":"crossref","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","article-title":"Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)","volume":"9","author":"Price","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.005_bib73","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.005_bib74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma","year":"2008","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.005_bib75","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.005_bib76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A\u00a0long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"10.1016\/j.hoc.2020.11.005_bib77","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.005_bib78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadie","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2020.11.005_bib79","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2020.11.005_bib80","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2020.11.005_bib81","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.005_bib82","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.005_bib83","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.005_bib84","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.hoc.2020.11.005_bib85","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.11.005_bib86","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:17Z","timestamp":1760184917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0889858820301490"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.11.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}